T. Rowe Price Associates
LHDX

T. Rowe Price Associates’s Lucira Health, Inc. Common Stock LHDX Stock Holding History

T. Rowe Price Associates’s Portfolio LHDX Stock Details LHDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-17,400
Closed -$32K – 3069
2022
Q2 		$32K Hold
17,400
– – ﹤0.01% 2907
2022
Q1 		$62K Hold
17,400
– – ﹤0.01% 2906
2021
Q4 		$150K Buy
17,400
+7,200
+71% +$45.8K ﹤0.01% 2812
2021
Q3 		$78K Sell
10,200
-4,600
-31% -$38.8K ﹤0.01% 2874
2021
Q2 		$98K Buy
+14,800
New +$93.3K ﹤0.01% 2851

Other funds holding LHDX

ECG
EPIQ Capital Group San Francisco, California $383M AUM 46.87% 1-Year Est. Return
EV
Eclipse Ventures Palo Alto, California $2.57B AUM
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
AA
AlphaCentric Advisors San Juan, Puerto Rico $118M AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return
LRPA
L. Roy Papp & Associates Phoenix, Arizona $951M AUM 29.05% 1-Year Est. Return
CWA
Consilio Wealth Advisors Bellevue, Washington $417M AUM 20.84% 1-Year Est. Return

T. Rowe Price Associates's LHDX Position: Q3 2022 in Review

T. Rowe Price Associates sold out of Lucira Health, Inc. Common Stock (LHDX) in Q3 2022, closing a stake of 17,400 shares — an estimated $32K sold.

T. Rowe Price Associates first reported a position in LHDX in Q2 2021 and held it in 5 quarters. The position peaked at $150K in Q4 2021. 28 funds tracked by Wall St. Rank hold LHDX as of Q3 2022.

  • T. Rowe Price Associates reported no remaining Lucira Health, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
  • T. Rowe Price Associates sold 17,400 Lucira Health, Inc. Common Stock shares in Q3 2022, an estimated $32K.
  • T. Rowe Price Associates first reported a position in Lucira Health, Inc. Common Stock in Q2 2021 and held it in 5 quarters.
  • T. Rowe Price Associates's Lucira Health, Inc. Common Stock position peaked at $150K in Q4 2021.
  • 28 funds tracked by Wall St. Rank held Lucira Health, Inc. Common Stock as of Q3 2022.

Based on T. Rowe Price Associates's 13F filing for Q3 2022, filed 14 Nov 2022.